

REGENERON PHARMACEUTICALS INC

Form 3

March 02, 2017

**FORM 3****UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB  
Number: 3235-0104Expires: January 31,  
2005Estimated average  
burden hours per  
response... 0.5**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF  
SECURITIES**Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting  
Person \*

Fenimore Christopher R.

(Last)

(First)

(Middle)

777 OLD SAW MILL RIVER  
RD

(Street)

TARRYTOWN, NY 10591

(City)

(State)

(Zip)

2. Date of Event Requiring  
Statement

(Month/Day/Year)

03/02/2017

3. Issuer Name and Ticker or Trading Symbol

REGENERON PHARMACEUTICALS INC [REGN]

4. Relationship of Reporting  
Person(s) to Issuer5. If Amendment, Date Original  
Filed(Month/Day/Year)

(Check all applicable)

☐ Director ☐ 10% Owner☒ Officer ☐ Other  
(give title below) (specify below)

VP, Controller

6. Individual or Joint/Group

Filing(Check Applicable Line)

☒ Form filed by One Reporting  
Person☐ Form filed by More than One  
Reporting Person**Table I - Non-Derivative Securities Beneficially Owned**1. Title of Security  
(Instr. 4)2. Amount of Securities  
Beneficially Owned  
(Instr. 4)3. Ownership  
Form:  
Direct (D)  
or Indirect  
(I)  
(Instr. 5)4. Nature of Indirect Beneficial  
Ownership  
(Instr. 5)

Common Stock

1,328

I

By 401(k) Plan

Common Stock

2,695

I

By GRAT

Common Stock

4,297

I

By Trust <sup>(1)</sup>Reminder: Report on a separate line for each class of securities beneficially  
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of  
information contained in this form are not  
required to respond unless the form displays a  
currently valid OMB control number.****Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**1. Title of Derivative Security  
(Instr. 4)2. Date Exercisable and  
Expiration Date  
(Month/Day/Year)3. Title and Amount of  
Securities Underlying

4. Conversion

5. Ownership

6. Nature of Indirect  
Beneficial

## Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 3

	Date Exercisable	Expiration Date	Derivative Security (Instr. 4)  Title	Amount or Number of Shares	or Exercise Price of Derivative Security	Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	Ownership (Instr. 5)
Incentive Stock Option (right to buy)	Â (2)	12/18/2019	Common Stock	1,375	\$ 21.25	D	Â
Incentive Stock Option (right to buy)	Â (2)	12/14/2020	Common Stock	4,280	\$ 30.63	D	Â
Incentive Stock Option (right to buy)	Â (2)	12/16/2021	Common Stock	2,224	\$ 52.03	D	Â
Non-Qualified Stock Option (right to buy)	Â (2)	12/16/2021	Common Stock	13,776	\$ 52.03	D	Â
Non-Qualified Stock Option (right to buy)	Â (3)	12/14/2022	Common Stock	23,500	\$ 179.13	D	Â
Non-Qualified Stock Option (right to buy)	Â (3)	12/13/2023	Common Stock	20,000	\$ 270.43	D	Â
Non-Qualified Stock Option (right to buy)	Â (3)	12/16/2026	Common Stock	12,283	\$ 381.92	D	Â
Non-Qualified Stock Option (right to buy)	Â (3)	12/16/2024	Common Stock	17,000	\$ 399.66	D	Â
Non-Qualified Stock Option (right to buy)	Â (3)	12/16/2025	Common Stock	14,450	\$ 555.67	D	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Fenimore Christopher R. 777 OLD SAW MILL RIVER RD TARRYTOWN, NY 10591	Â	Â	Â VP, Controller	Â

## Signatures

/s/\*\*Christopher R.  
Fenimore

03/02/2017

\*\*Signature of Reporting  
Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These shares are held in a trust for the benefit of the reporting person's spouse. The reporting person and the reporting person's spouse are trustees of the trust.

## Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 3

- (2) The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.
- (3) The stock option award vests in four equal annual installments, commencing one year after the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.